Profile

Artisan Pharma is a U.S. biotechnology company formed in 2006 as a partnership between a group of Asian and Western investors led by NGN Capital and Asahi Kasei Pharma Corporation Corporation (AKP). Our lead product, ART 123, is a late-stage biologic drug candidate in-licensed from AKP.

A new, separate, independent entity, Artisan has a mission to become a leading critical-care pharmaceutical company. By blending a high degree of skill with world-class R&D, corporate development and operational competencies, we aim to generate the maximum benefit to patients and the maximum value to our shareholders.

Our management team brings a unique combination of corporate development, drug development, strategic alliance and venture capital experience – including the formation and launch of several firms similar to Artisan.

To assist Artisan in the development and commercialization of ART 123, we have recruited an ART 123 Program Advisory Board consisting of the finest research minds in sepsis, critical care and hematology. Meanwhile, our investor syndicate will help drive our corporate value by leveraging regional resources with a global relationship network.